Welcome!

News Feed Item

New Research Highlights an Investigational Single-Entity Formulation Hydrocodone Bitartrate Extended-Release Tablet at PAINWeek

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential  in recreational opioid abusers at PAINWeek national conference Sept. 2 – 6 in Las Vegas.

Purdue Pharma, L.P. logo.

Purdue Pharma's investigational pain medication, once-daily hydrocodone bitartrate (which is expected to be marketed under the trade name, Hysingla™ ER) is a single-entity product that does not include acetaminophen.  The tablets are formulated with abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by various routes of administration (e.g., chewing, snorting and intravenous injection).

Highlights of three of the several posters presented this week are as follows:

  • One poster, titled "Evaluation of once-daily hydrocodone (Hysingla™ ER) in users of immediate-release hydrocodone combination products," analyzed the analgesic effectiveness and safety of single-entity hydrocodone (Hysingla ER) in 20 mg to 120 mg tablets dosed once daily among patients with moderate to severe chronic pain and who were transitioning from hydrocodone  products that are combined with acetaminophen.  Data were from two phase 3 studies: a 12-week, placebo-controlled, double-blind study, and an open-label, long-term study with a 12-month maintenance treatment period. Among these patients in the placebo-controlled study, Hysingla ER (N=62) showed clinically meaningful and statistically significant pain relief at week 12 compared to placebo (N=67) in both primary and sensitivity analyses (deltas=0.64 to 0.98; P's = .0078 to .0357). Among patients in the long-term study, clinically significant improvements from baseline in pain relief (e.g., 30% reduction in pain) were achieved with Hysingla ER treatment, and these treatment effects were maintained throughout 12-month treatment period. Among patients who had previously used hydrocodone/acetaminophen products, adverse events were consistent with those associated with opioid analgesics. The most common treatment-emergent adverse events included constipation, nausea, vomiting, dizziness, and headache.
  • The next study, which is the first of two studies being presented on abuse potential, titled "Intranasal Abuse Potential Study of a Once-Daily, Single-Entity, Extended-Release Hydrocodone Tablet (Hysingla™ ER) in Recreational Opioid Users," compared the intranasal abuse potential of fine-milled and coarse-milled Hysingla ER (using an industrial mill and razor blade, respectively) to that of hydrocodone powder and placebo. Abuse potential was evaluated using pharmacokinetic measures of plasma samples and subjective pharmacodynamic measures of drug liking.
    • The pharmacokinetic data showed that subjects had a higher concentration of hydrocodone in the blood following hydrocodone powder than they did following use of either fine-milled or coarse-milled Hysingla.
    • The pharmacodynamic assessment showed that mean scores for overall drug liking were highest for hydrocodone powder followed by the two tampered Hysingla ER treatments and placebo. Compared with hydrocodone powder:
      • 68 percent of subjects using coarse-milled Hysingla ER had a reduction of at least 30 percent in drug liking where 64 percent had a reduction of at least 50 percent, and 44 percent had a reduction of at least 90 percent.
      • 72 percent of subjects using fine-milled Hysingla ER had a reduction of at least 30 percent in drug liking where 64 percent had a reduction of at least 50 percent, and 36 percent had a reduction of at least 90 percent.
  • The second of the two abuse-potential studies presented, titled "Oral Abuse Potential Study of a Once-Daily, Single-Entity, Extended-Release Hydrocodone Tablet (Hysingla™ ER) in Recreational Opioid Users," compared the oral abuse potential of Hysingla ER when chewed or when milled with an industrial mill to that of the intact Hysingla ER, immediate release hydrocodone solution and placebo. Abuse potential was evaluated using pharmacokinetic measures of plasma samples and subjective pharmacodynamic measures of drug liking.
    • The pharmacokinetic results showed higher concentrations of hydrocodone among subjects using immediate release hydrocodone solution than subjects using milled, chewed or intact Hysingla ER, and the  time to achieve maximum concentration was faster among subjects using hydrocodone IR than those using milled, chewed or intact Hysingla ER
    • The pharmacodynamic assessments showed that mean scores for overall drug liking were highest for hydrocodone IR solution and milled Hysingla ER. Compared to the hydrocodone IR solution:
      • 83 percent of subjects using intact Hysingla ER had a reduction of at least 30 percent in drug liking where 74 percent had a reduction of at least 50 percent, and 37 percent had a reduction of at least 90 percent.
      • 69 percent of subjects using chewed Hysingla ER had a reduction of at least 30 percent in drug liking where 60 percent had a reduction of at least 50 percent, and 29 percent had a reduction of at least 90 percent.
      • 17 percent of subjects using milled Hysingla ER had a reduction of at least 30 percent in drug liking where 9 percent had a reduction of at least 50 percent, and 6 percent had a reduction of at least 90 percent.

"These studies continue to support the fact that, if approved by the Food and Drug Administration, Hysingla ER could be an important alternative for healthcare professionals treating patients in chronic pain with a hydrocodone product formulated with physicochemical properties intended to deter abuse," said Todd Baumgartner, M.D., MPH, Vice President of Research & Development and Chief Medical Officer at Purdue Pharma which funded the research.

The opioid hydrocodone in combination with acetaminophen (Vicodin® and its generic formulations) is the most commonly prescribed opioid analgesics in the United States.1 However, acetaminophen may cause liver toxicity (i.e., hepatotoxicity), including serious liver failure, when a patient exceeds the total recommended dosage of less than 4g per day,2 prompting the need for an extended release option without acetaminophen.

Immediate release hydrocodone combination products are also the most widely abused (nonmedical use) according to the Substance Abuse and Mental Health Services Administration.3 Currently available hydrocodone formulations do not incorporate abuse-deterrent technologies. 

The U.S. Food and Drug Administration (FDA) recently granted Priority Review designation to Purdue's new drug application requesting approval to market Hysingla ER, which incorporates abuse-deterrent properties.

About Chronic Pain
Purdue is a leader in developing treatment options for the management of chronic pain, which is one of the most common reasons for visits to healthcare professionals. Chronic pain conditions affect more than 100 million U.S. adults and cost the American economy as much as $635 billion each year in direct healthcare expenses and lost productivity.

About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on chronic pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

1 U.S. Pharmaceutical Sales - Q4 2013, Drugs.com, Accessed 09/04/2014
2 Ferguson E, Nelson L. 2009. Silver Spring, MD: Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM179888.pdf. Accessed 09/04/14.
3 2012 National Household Survey on Drug Use and Health, Table 1.89A, Substance Abuse and Mental Health Services Administration.  Accessed 09/04/2014

Logo - http://photos.prnewswire.com/prnh/20100921/NY67262

SOURCE Purdue Pharma L.P.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...